Steven Zeldenrust
Overview
Explore the profile of Steven Zeldenrust including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Warsame R, Kasi P, Villasboas-Bisneto J, Gallenberg D, Wolf R, Ward J, et al.
J Oncol Pract
. 2015 Sep;
12(1):e88-94.
PMID: 26374861
Purpose: To develop a care model to decrease incidence of preventable errors in the complex multidisciplinary care of hematology inpatients at the time of discharge. Methods: An interactive, multidisciplinary, structured...
22.
Dispenzieri A, Gertz M, Saenger A, Kumar S, Lacy M, Buadi F, et al.
Am J Hematol
. 2015 Mar;
90(6):524-8.
PMID: 25753178
The use of soluble cardiac biomarkers such as N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin has revolutionized prognostication for patients with AL amyloidosis. Soluble ST2 (sST2) and galectin-3 have also...
23.
Kourelis T, Kumar S, Gertz M, Lacy M, Buadi F, Hayman S, et al.
J Clin Oncol
. 2013 Oct;
31(34):4319-24.
PMID: 24145344
Purpose: There is consensus that patients with light chain (AL) amyloidosis with hypercalcemia, renal failure, anemia, and lytic bone lesions attributable to clonal expansion of plasma cells (CRAB criteria) also...
24.
DSouza A, Theis J, Quint P, Kyle R, Gertz M, Zeldenrust S, et al.
Am J Hematol
. 2013 Apr;
88(7):577-80.
PMID: 23606017
Amyloidosis affecting lymph nodes (LN) may occur in the setting of systemic amyloidosis or as an entity localized to the site of production (peritumoral). Why some LN amyloid remains peritumoral...
25.
Kourelis T, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, et al.
Am J Hematol
. 2013 Mar;
88(5):375-8.
PMID: 23508840
To clarify the presentation and course of patients with chronic lymphocytic leukemia (CLL) and amyloidosis. Mayo databases were interrogated for patients who carried a diagnosis of amyloidosis and CLL evaluated...
26.
Ruberg F, Maurer M, Judge D, Zeldenrust S, Skinner M, Kim A, et al.
Am Heart J
. 2012 Aug;
164(2):222-228.e1.
PMID: 22877808
Background: TRACS sought to describe the clinical outcomes and disease progression of transthyretin (TTR) cardiac amyloidosis (ATTR) in an observational study. Clinical course is largely determined by disease type with...
27.
DSouza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, et al.
Blood
. 2012 May;
120(1):56-62.
PMID: 22611150
The POEMS syndrome (polyradiculoneuropathy, organomegaly, multiple endocrinopathies, monoclonal protein, skin changes) is a rare disease associated with a plasma cell dyscrasia. Patients with disseminated POEMS can be treated with high-dose...
28.
Stangou A, Lobato L, Zeldenrust S, Rela M, Portmann B, Linke R, et al.
Amyloid
. 2012 May;
19 Suppl 1:81-4.
PMID: 22540225
Fibrinogen A α-chain (AFib) and apolipoprotein AI (AApoAI) amyloidosis due to variants in the AFib and ApoAI genes are the most common types of hereditary amyloidosis in Europe and the...
29.
DSouza A, Hayman S, Buadi F, Mauermann M, Lacy M, Gertz M, et al.
Blood
. 2011 Sep;
118(17):4663-5.
PMID: 21881050
The POEMS syndrome is associated with elevated vascular endothelial growth factor (VEGF) levels. Several studies have compared serum VEGF levels between POEMS patients and other disease entities showing higher serum...
30.
Lacy M, Allred J, Gertz M, Hayman S, Short K, Buadi F, et al.
Blood
. 2011 Jun;
118(11):2970-5.
PMID: 21690557
Pomalidomide at doses of 2 or 4 mg/d has demonstrated excellent activity in patients with multiple myeloma (MM). We opened 2 sequential phase 2 trials using the pomalidomide with weekly...